Free tool
FAERS Monitor: Illuccix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214032 or its brand name (Illuccix, Gallium Ga-68 Gozetotide). Reports on generic versions are filed under their own applications.
Reports
194
Serious
17
9% of reports
Hospitalization
5
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain128
- burning sensation9
- injection site discomfort8
- positron emission tomogram abnormal7
- loss of consciousness5
- syncope5
- chest pain4
- drug ineffective4
- product preparation error4
- seizure4
- diarrhoea3
- injection site haemorrhage3
- pain3
- vomiting3
- blood glucose decreased2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 27 |
| 2023 | 58 |
| 2024 | 53 |
| 2025 | 44 |
| 2026 | 12 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,965 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| positron emission tomogram abnormalSignal | 7 | 1097.8 | 528.4 | 6,547 |
| injection site discomfortSignal | 8 | 82.5 | 41.9 | 565 |
| injection site painSignal | 128 | 45.3 | 40.9 | 5,575 |
| product preparation errorSignal | 4 | 21.1 | 8.0 | 58 |
| burning sensationSignal | 9 | 13.9 | 7.4 | 96 |
| syncopeSignal | 5 | 5.4 | 2.3 | 14 |
| blood glucose decreased | 2 | 4.5 | 1.1 | 3 |
| loss of consciousnessSignal | 5 | 4.2 | 1.8 | 9 |
| injection site haemorrhageSignal | 3 | 4.1 | 1.3 | 4 |
| seizureSignal | 4 | 3.8 | 1.4 | 6 |
| chest pain | 4 | 2.3 | 0.9 | 2 |
| vomiting | 3 | 0.7 | 0.2 | 0 |
| pain | 3 | 0.5 | 0.2 | 1 |
| diarrhoea | 3 | 0.5 | 0.2 | 1 |
| drug ineffective | 4 | 0.3 | 0.1 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.